Zartra (imiquimod)
- Region
- 🇪🇺 EU
- Active substance
- imiquimod
- Company
- Laboratoires 3M Santé
- Status
- Withdrawn
- Therapeutic area
- Condylomata Acuminata
- EU approval
- Fri 18 Sep 1998
- Application
- EMEA/H/C/000180
- ATC
- L03AX
- Official record
- www.ema.europa.eu
Indication
Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Aldara Authorised · Viatris Healthcare Limited
- 🇪🇺 Zyclara Authorised · Viatris Healthcare Limited
Follow Zartra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.